Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
All 178 HIV-infected individuals who had initiated tenofovir-emtricitabine-nevirapine (TDF/FTC/NVP) at our institution and were adherent to their medication were retrospectively examined. Only 22% were antiretroviral naive. After a median follow-up of 16 months, only five (2.8%) individuals (all with prior exposure to other antiretroviral regimens) experienced virological failure. In all instances, viral rebound occurred after 12 weeks of therapy. These results do not support an increased risk of early virological failure using TDF/FTC/NVP.
Labarga
Pablo
P
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Medrano
Jose
J
Seclen
Eduardo
E
Poveda
Eva
E
Rodriguez-Novoa
Sonia
S
Morello
Judit
J
de Mendoza
Carmen
C
Vispo
Eugenia
E
Soriano
Vincent
V
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage*; D063065:Organophosphonates / Q000008:administration & dosage*; D012367:RNA, Viral; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D063065:Organophosphonates; D012367:RNA, Viral; D003841:Deoxycytidine; D019829:Nevirapine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine